| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Purchases of marketable securities | 6,590,939 | 6,588,577 |
| Net cash provided by investing activities | 26,602,830 | 24,427,935 |
| Issuance of common stock related to at-the-market offering, net of offering costs | 1,313,929 | 783,746 |
| Issuance of common stock related to registered direct offering, net of offering costs | 3,528,269 | - |
| Net cash provided by financing activities | 4,842,198 | 783,746 |
| Net increase (decrease) in cash and cash equivalents | 8,507,399 | 8,178,637 |
| Cash and cash equivalents at beginning of period | 2,936,544 | - |
| Cash and cash equivalents at end of period | 11,443,943 | - |
Co-Diagnostics, Inc. (CODX)
Co-Diagnostics, Inc. (CODX)